ALDEA Pharmaceuticals is developing a number of small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) superfamily.

This proprietary scientific approach was originally discovered by Stanford University researchers and exclusively licensed to Aldea. With its ALDH platform, ALDEA has the unique opportunity to pursue novel targets across multiple therapeutics areas to address significant unmet medical needs.

• Acute alcohol toxicity
• Fanconi anemia
• Alcohol metabolism deficiency (ALMD) and it's long term consequences
• Other diseases and conditions associated with toxic aldehydes